» Articles » PMID: 25496518

Whole Exome Sequencing of a Single Osteosarcoma Case--integrative Analysis with Whole Transcriptome RNA-seq Data

Overview
Journal Hum Genomics
Publisher Biomed Central
Specialty Genetics
Date 2014 Dec 16
PMID 25496518
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Osteosarcoma (OS) is a prevalent primary malignant bone tumour with unknown etiology. These highly metastasizing tumours are among the most frequent causes of cancer-related deaths. Thus, there is an urgent need for different markers, and with our study, we were aiming towards finding novel biomarkers for OS.

Methods: For that, we analysed the whole exome of the tumorous and non-tumour bone tissue from the same patient with OS applying next-generation sequencing. For data analysis, we used several softwares and combined the exome data with RNA-seq data from our previous study.

Results: In the tumour exome, we found wide genomic rearrangements, which should qualify as chromotripsis-we detected almost 3,000 somatic single nucleotide variants (SNVs) and small indels and more than 2,000 copy number variants (CNVs) in different chromosomes. Furthermore, the somatic changes seem to be associated to bone tumours, whereas germline mutations to cancer in general. We confirmed the previous findings that the most significant pathway involved in OS pathogenesis is probably the WNT/β-catenin signalling pathway. Also, the IGF1/IGF2 and IGF1R homodimer signalling and TP53 (including downstream tumour suppressor gene EI24) pathways may have a role. Additionally, the mucin family genes, especially MUC4 and cell cycle controlling gene CDC27 may be considered as potential biomarkers for OS.

Conclusions: The genes, in which the mutations were detected, may be considered as targets for finding biomarkers for OS. As the study is based on a single case and only DNA and RNA analysis, further confirmative studies are required.

Citing Articles

Imaging, clinical, and histopathological challenges in diagnosing retroperitoneal extraskeletal osteosarcoma.

Ichikawa J, Kawasaki T, Onohara K, Wako M, Taniguchi N, Ochiai S Front Oncol. 2025; 15:1454055.

PMID: 40078181 PMC: 11896851. DOI: 10.3389/fonc.2025.1454055.


Genetics and Molecular Pathogenesis of the Chondrosarcoma: A Review of the Literature.

Iacobescu G, Corlatescu A, Serban B, Spiridonica R, Costin H, Cirstoiu C Curr Issues Mol Biol. 2024; 46(11):12658-12671.

PMID: 39590345 PMC: 11593320. DOI: 10.3390/cimb46110751.


The combination of apatinib and antigen-specific DC-induced T cells exert antitumor effects by potently improving the immune microenvironment of osteosarcoma.

Hu T, Sun W, Jin Y, Dong Y, Liu W, Sun Z Heliyon. 2024; 10(16):e36016.

PMID: 39224314 PMC: 11367533. DOI: 10.1016/j.heliyon.2024.e36016.


A Primary Telangiectatic Mandibular Osteosarcoma With Germ-Line Malignancy-Associated DNA Damage Repair Gene Polymorphisms: A Case Report.

Tahir M, Wei E, Madelaire C, Yu A, Herrera G, Shackelford R Case Rep Oncol Med. 2024; 2024:2418888.

PMID: 38962713 PMC: 11221979. DOI: 10.1155/2024/2418888.


Up-regulation of NCAPG mediated by E2F1 facilitates the progression of osteosarcoma through the Wnt/β-catenin signaling pathway.

Luo G, Cheng H, Fan J, Sun T Transl Cancer Res. 2024; 13(5):2437-2450.

PMID: 38881929 PMC: 11170535. DOI: 10.21037/tcr-23-2175.


References
1.
Lv Z, Wang C, Yuan T, Liu Y, Song T, Liu Y . Bone morphogenetic protein 9 regulates tumor growth of osteosarcoma cells through the Wnt/β-catenin pathway. Oncol Rep. 2013; 31(2):989-94. DOI: 10.3892/or.2013.2931. View

2.
Pant V, Jambhekar N, Madur B, Shet T, Agarwal M, Puri A . Anaplastic large cell lymphoma (ALCL) presenting as primary bone and soft tissue sarcoma--a study of 12 cases. Indian J Pathol Microbiol. 2007; 50(2):303-7. View

3.
Allison D, Carney S, Ahlmann E, Hendifar A, Chawla S, Fedenko A . A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma. 2012; 2012:704872. PMC: 3329715. DOI: 10.1155/2012/704872. View

4.
Cai Y, Cai T, Chen Y . Wnt pathway in osteosarcoma, from oncogenic to therapeutic. J Cell Biochem. 2013; 115(4):625-31. DOI: 10.1002/jcb.24708. View

5.
Tarkkanen M, Elomaa I, Blomqvist C, Kivioja A, Kellokumpu-Lehtinen P, Bohling T . DNA sequence copy number increase at 8q: a potential new prognostic marker in high-grade osteosarcoma. Int J Cancer. 1999; 84(2):114-21. DOI: 10.1002/(sici)1097-0215(19990420)84:2<114::aid-ijc4>3.0.co;2-q. View